World's Best Scientists 2026 revealed!
Armando Santoro

Armando Santoro

Award Badge
Medicine
Italy
2023

D-Index & Metrics

Medicine

D-Index
130
Citations
86090
World Ranking
2441
National Ranking
54

Research.com Recognitions

  • 2023 - Research.com Medicine in Italy Leader Award

Overview

Armando Santoro is affiliated with Humanitas University in Italy and has made contributions primarily in the field of Medicine, with a strong focus on Oncology. Their research covers several subfields including Pulmonary and Respiratory Medicine, Pathology and Forensic Medicine, Radiology, Nuclear Medicine and Imaging, and Genetics.

The scientist's work frequently addresses topics related to cancer diagnosis, treatment, and immunotherapy. Key research topics include Lymphoma Diagnosis and Treatment, Cancer Immunotherapy and Biomarkers, CAR-T cell therapy research, Chronic Lymphocytic Leukemia Research, Advanced Breast Cancer Therapies, Lung Cancer Treatments and Mutations, and Cancer Genomics and Diagnostics.

Recent notable papers include:

  • "Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients With Advanced Hepatocellular Carcinoma Previously Treated With Sorafenib" (2020, JAMA Oncology)
  • "Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer" (2021, Annals of Oncology)
  • "Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma" (2021, New England Journal of Medicine)
  • "Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial" (2020, The Lancet Oncology)
  • "PD-1 Blockade in Anaplastic Thyroid Carcinoma" (2020, Journal of Clinical Oncology)

The list of frequent co-authors highlights ongoing collaborative research efforts within the scientific community. These co-authors include Laura Giordano, Stéfania Bramanti, Rita De Sanctis, Carmelo Carlo-Stella, and Rosalba Torrisi.

Armando Santoro's work appears regularly in several publication venues, with a significant number of publications featured in Zenodo (CERN European Organization for Nuclear Research), Blood, Journal of Clinical Oncology, Cancers, and Annals of Oncology.

Best Publications

  • Sorafenib in Advanced Hepatocellular Carcinoma

    Josep M. Llovet;Sergio Ricci;Vincenzo Mazzaferro;Philip Hilgard

  • Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer.

    David Cunningham;Yves Humblet;Salvatore Siena;David Khayat

  • Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX™/Doxil®) versus conventional doxorubicin for first-line treatment of metastatic breast cancer

    Mary E R O'Brien;N. Wigler;M. Inbar;R. Rosso

  • Ceritinib in ALK-Rearranged Non–Small-Cell Lung Cancer

    Alice T. Shaw;Dong Wan Kim;Ranee Mehra;Daniel S W Tan

  • Phase II Study of Sorafenib in Patients With Advanced Hepatocellular Carcinoma

    Ghassan K. Abou-Alfa;Lawrence Schwartz;Sergio Ricci;Dino Amadori

  • Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients With Advanced Hepatocellular Carcinoma Previously Treated With Sorafenib: The CheckMate 040 Randomized Clinical Trial.

    Thomas Yau;Yoon Koo Kang;Tae You Kim;Anthony B. El-Khoueiry

  • Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial

    Anas Younes;Armando Santoro;Margaret Shipp;Pier Luigi Zinzani

  • Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial.

    Jordi Bruix;Jean Luc Raoul;Morris Sherman;Vincenzo Mazzaferro

  • Nivolumab for Relapsed/Refractory Classic Hodgkin Lymphoma After Failure of Autologous Hematopoietic Cell Transplantation: Extended Follow-Up of the Multicohort Single-Arm Phase II CheckMate 205 Trial.

    Philippe Armand;Andreas Engert;Anas Younes;Michelle A Fanale

  • Prognostic factors for the outcome of chemotherapy in advanced soft tissue sarcoma: an analysis of 2,185 patients treated with anthracycline-containing first-line regimens--a European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study.

    M. Van Glabbeke;A.T. van Oosterom;J.W. Oosterhuis;H. Mouridsen

  • Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group.

    A Santoro;T Tursz;H Mouridsen;Jaap Verweij

  • Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial

    Steven Horwitz;Owen A O'Connor;Barbara Pro;Tim Illidge

  • Tivantinib for second-line treatment of advanced hepatocellular carcinoma: A randomised, placebo-controlled phase 2 study

    Armando Santoro;Lorenza Rimassa;Ivan Borbath;Bruno Daniele

  • Sorafenib: a review of its use in advanced hepatocellular carcinoma.

    Gillian M Keating;Armando Santoro

  • Increased MET Gene Copy Number Negatively Affects Survival of Surgically Resected Non–Small-Cell Lung Cancer Patients

    Federico Cappuzzo;Antonio Marchetti;Margaret Skokan;Elisa Rossi

  • Effect of everolimus on survival in advanced hepatocellular carcinoma after failure of sorafenib: the EVOLVE-1 randomized clinical trial.

    Andrew X. Zhu;Masatoshi Kudo;Eric Assenat;Stéphane Cattan

  • SEARCH: A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Sorafenib Plus Erlotinib in Patients With Advanced Hepatocellular Carcinoma

    Andrew X. Zhu;Olivier Rosmorduc;T. R Jeffry Evans;Paul J. Ross

  • Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trial

    Evan W Alley;Juanita Lopez;Armando Santoro;Anne Morosky

  • Identifying and Targeting ROS1 Gene Fusions in Non–Small Cell Lung Cancer

    Kurtis D. Davies;Anh T. Le;Mariana F. Theodoro;Margaret C. Skokan

  • Gonadal toxicity after combination chemotherapy for Hodgkin's disease. Comparative results of MOPP vs ABVD.

    S. Viviani;A. Santoro;G. Ragni;V. Bonfante

Frequent Co-Authors

Pier Luigi Zinzani
Pier Luigi Zinzani University of Bologna
Paolo Corradini
Paolo Corradini University of Milan
Camillo Porta
Camillo Porta University of Bari Aldo Moro
Martin Dreyling
Martin Dreyling Ludwig-Maximilians-Universität München
Claudio Bordignon
Claudio Bordignon MolMed (Italy)
Umberto Tirelli
Umberto Tirelli National Institutes of Health
Arnon Nagler
Arnon Nagler Sheba Medical Center
Federico Cappuzzo
Federico Cappuzzo Azienda Unità Sanitaria Locale Della Romagna
Roberto Labianca
Roberto Labianca Mario Negri Institute for Pharmacological Research
Pinuccia Valagussa
Pinuccia Valagussa University of Louisville

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For students interested in healthcare careers beyond medicine, there are many affordable and flexible online degree options. Nursing is a popular pathway, and many wonder what is the cheapest online college for nursing?. Choosing a budget-friendly online nursing program can help minimize student debt while still gaining the necessary credentials.

For registered nurses looking to advance their education, there are most affordable accredited online rn to bsn programs that allow for career growth and increased earning potential. Those who already have experience in nursing and are interested in research or university-level teaching may want to explore online phd programs nursing, which offer flexible learning while reaching the highest levels of education in nursing.

If you hold a non-nursing bachelor’s degree, you might consider taking the accelerated route through cheapest direct entry msn programs. These programs fast-track students into advanced nursing roles, making a career change both practical and cost-effective. Exploring these online degrees expands your career prospects in the healthcare sector.

Best Scientists Citing Armando Santoro

Trending Scientists